You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

209 Results
Guidelines and Advice
Status: Current
ID: PET 2024-1
Mar 2025
Document
Apr 2025
Document
May 2025
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
EPIrubicin,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
Drug
Other Name(s): Elrexfio™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2025
Document
New
Nov 2025
Document
New
Nov 2025
Document
New
Nov 2025
Document
New
Nov 2025
Document
New
Nov 2025
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
DACTINomycin,
etoposide,
methotrexate,
leucovorin,
cyclophosphamide,
vinCRIStine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Dec 2025
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
PACLitaxel,
CISplatin,
etoposide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Dec 2025

Pages